| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/27/2000 | WO2000023113A1 Peptide-based carrier devices for stellate cells |
| 04/27/2000 | WO2000023112A1 Modulation of gene expression by combination therapy |
| 04/27/2000 | WO2000023110A1 Methods and agents for inducing apoptosis and methods for their identification |
| 04/27/2000 | WO2000023109A1 Glypicans for the detection and treatment of human carcinoma |
| 04/27/2000 | WO2000023102A1 Method for regulating the permeability of the blood brain barrier |
| 04/27/2000 | WO2000023101A1 Methods for treating sepsis |
| 04/27/2000 | WO2000023100A2 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 04/27/2000 | WO2000023099A1 Insulin preparations for pulmonary delivery containing menthol |
| 04/27/2000 | WO2000023098A1 Stable concentrated insulin preparations for pulmonary delivery |
| 04/27/2000 | WO2000023097A1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia |
| 04/27/2000 | WO2000023096A2 Combination therapy with vip antagonist |
| 04/27/2000 | WO2000023095A2 Method of modulating hair growth |
| 04/27/2000 | WO2000023094A2 Methods of inhibiting platelet activation and recruitment |
| 04/27/2000 | WO2000023093A1 Compositions and methods for promoting tissue repair using heat shock proteins |
| 04/27/2000 | WO2000023092A1 Contulakin-g, analogs thereof and uses therefor |
| 04/27/2000 | WO2000023091A2 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 04/27/2000 | WO2000023087A1 Polyspecific binding molecules and uses thereof |
| 04/27/2000 | WO2000023084A1 Methods for stimulating the regeneration of inner ear cells |
| 04/27/2000 | WO2000023083A1 Neuroprotective truncated bax polypeptides |
| 04/27/2000 | WO2000023082A1 Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| 04/27/2000 | WO2000022937A1 Protein material for slow digestion and its use |
| 04/27/2000 | WO2000007014A3 Leptin-mediated gene-induction |
| 04/27/2000 | WO2000006742A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 04/27/2000 | WO2000005407A3 DUPLICATIONS OF HUMAN CHROMOSOME 15q24-25 AND ANXIETY DISORDERS, DIAGNOSTIC METHODS FOR THEIR DETECTION |
| 04/27/2000 | WO2000005255A3 Anti-inflammatory compounds |
| 04/27/2000 | WO2000004141A3 Use of nucleic acid molecules as antiviral agents |
| 04/27/2000 | WO2000001802A3 Peptide antagonists of the human urokinase receptor and method for selecting them |
| 04/27/2000 | WO2000001732A3 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 04/27/2000 | WO1999067382A3 Angiopoietin-like growth factor sequences |
| 04/27/2000 | WO1999064586A3 Phagocytic assay method |
| 04/27/2000 | WO1999063933A9 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 04/27/2000 | WO1999062459A9 Agents and methods for protection, treatment and repair of connective tissue |
| 04/27/2000 | WO1999061085A9 Method and compositions for treatment of cancers |
| 04/27/2000 | WO1999059545A9 Targeted liposomal drug delivery system |
| 04/27/2000 | WO1999057271A9 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides |
| 04/27/2000 | DE19856210A1 Use of thiol compound selected from oxidoreductase and/or hydrolase for treatment of chronic and acute tinnitus |
| 04/27/2000 | DE19849044A1 New polycythemia rubra vera-related polypeptide useful for diagnosis and for developing therapeutic antibodies |
| 04/27/2000 | CA2749553A1 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 04/27/2000 | CA2622786A1 Neovascular-specific peptides |
| 04/27/2000 | CA2364330A1 Secreted protein zsig49 |
| 04/27/2000 | CA2354862A1 Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| 04/27/2000 | CA2348153A1 Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules |
| 04/27/2000 | CA2348068A1 Adeno-associated vectors for expression of factor viii by target cells |
| 04/27/2000 | CA2347937A1 Method for the production of purified invasin protein and use thereof |
| 04/27/2000 | CA2347654A1 Human rna binding proteins |
| 04/27/2000 | CA2347625A1 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 04/27/2000 | CA2347450A1 P53 binding areas |
| 04/27/2000 | CA2347250A1 Methods for treating sepsis |
| 04/27/2000 | CA2347204A1 Compositions and methods for promoting tissue repair using heat shock proteins |
| 04/27/2000 | CA2347172A1 Protein material for slow digestion and its use |
| 04/27/2000 | CA2347136A1 Neovascular-specific peptides |
| 04/27/2000 | CA2347080A1 Tnfr related gene 12 |
| 04/27/2000 | CA2347062A1 Multiple domain glycoprotein hormones and methods of using |
| 04/27/2000 | CA2347003A1 Modulation of gene expression by combination therapy |
| 04/27/2000 | CA2346969A1 Stable concentrated insulin preparations for pulmonary delivery |
| 04/27/2000 | CA2346942A1 Camel, an alternative translation product of the tumour antigen lage-1 |
| 04/27/2000 | CA2346937A1 Specific therapeutic interventions obtained by interference with redistribution and/or targeting |
| 04/27/2000 | CA2346884A1 Insulin preparations for pulmonary delivery containing menthol |
| 04/27/2000 | CA2346866A1 Combination therapy with vip antagonist |
| 04/27/2000 | CA2346799A1 Delivery system for porcine somatotropin |
| 04/27/2000 | CA2346798A1 Novel neuropilin/growth factor binding and uses thereof |
| 04/27/2000 | CA2346500A1 Methods and reagents for isolating biologically active peptides |
| 04/27/2000 | CA2346264A1 Glypicans for the detection and treatment of human carcinoma |
| 04/27/2000 | CA2345938A1 Polymorphism in a tgf-beta gene correlated to osteoporosis |
| 04/27/2000 | CA2345382A1 Inhibitors of platelet activation and recruitment |
| 04/27/2000 | CA2344605A1 G-protein coupled receptors |
| 04/27/2000 | CA2343094A1 Interferon-beta fusion proteins and uses |
| 04/27/2000 | CA2342794A1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia |
| 04/27/2000 | CA2251860A1 Methods for modulating the length of telomeres by modulating the level or activity of the protease involved in the conversion of hnrnpa1 into up1 |
| 04/26/2000 | EP0995798A1 Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| 04/26/2000 | EP0995761A2 Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| 04/26/2000 | EP0995759A1 Angiopoietin related gene sequence scarface 2 |
| 04/26/2000 | EP0995758A1 Physiologically active polyoxypeptin and deoxypolyoxypeptin and anticancer drugs containing the same |
| 04/26/2000 | EP0995756A2 Mechanism oriented inhibitors of dipeptidyl peptidase I |
| 04/26/2000 | EP0995755A1 Prodrugs of Thrombin inhibitors |
| 04/26/2000 | EP0995446A2 Antithrombin III-beta containing medical preparation |
| 04/26/2000 | EP0995445A2 Ligand-mediated immunofunctional hormone binding protein assay method |
| 04/26/2000 | EP0995444A2 Systemic Therapy of pain and depressive sensitivity |
| 04/26/2000 | EP0995440A1 Method to increase the blood, glucose level in mammals |
| 04/26/2000 | EP0995118A1 Chaperone fragments |
| 04/26/2000 | EP0994966A1 Member of the tnf family useful for treatment and diagnosis of disease |
| 04/26/2000 | EP0994948A1 TGF$g(b) RII RECEPTOR NUCLEIC SEQUENCE, CODED PEPTIDE, AND USES |
| 04/26/2000 | EP0994947A1 Mu-1, member of the cytokine receptor family |
| 04/26/2000 | EP0994946A1 Coding sequence haplotypes of the human brca2 gene |
| 04/26/2000 | EP0994945A2 Smad-interacting polypeptides and their use |
| 04/26/2000 | EP0994903A1 Methods and compositions for galactosylated glycoproteins |
| 04/26/2000 | EP0994902A1 Cyclic crf antagonist peptides |
| 04/26/2000 | EP0994901A1 Method for extracting, identifying, using active principles of marine mollusque shells |
| 04/26/2000 | EP0994900A1 Semaphorin receptors |
| 04/26/2000 | EP0994899A2 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM |
| 04/26/2000 | EP0994898A1 Integrin binding peptide and use thereof |
| 04/26/2000 | EP0994897A1 Mu-opiate receptor peptides |
| 04/26/2000 | EP0994896A1 Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/26/2000 | EP0994895A1 Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/26/2000 | EP0994894A1 SELECTIVE FACTOR Xa INHIBITORS |
| 04/26/2000 | EP0994893A1 Selective factor xa inhibitors containing a fused azepinone structure |
| 04/26/2000 | EP0994892A1 SELECTIVE FACTOR Xa INHIBITORS |
| 04/26/2000 | EP0994887A2 Modified glycosides, compositions comprised thereof and methods of use thereof |
| 04/26/2000 | EP0994728A1 Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| 04/26/2000 | EP0994724A1 Methods and compositions for impairing multiplication of hiv-1 |